Trial Profile
A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Terevalefim (Primary)
- Indications Myocardial infarction
- Focus Pharmacodynamics
- Sponsors Angion Biomedica
- 29 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 18 Jul 2012 The first patient has been treated, according to an Angion Biomedica media release
- 13 Jul 2012 Planned end date changed from 1 Jul 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.